Incidence and clearance of anal high-risk Human Papillomavirus infection and their risk factors in men who have sex with men living with HIV (vol 12, 184, 2022)

被引:0
作者
Dona, Maria Gabriella
Giuliani, Massimo
Rollo, Francesca
Vescio, Maria Fenicia
Benevolo, Maria
Giglio, Amalia
Giuliani, Eugenia
Morrone, Aldo
Latini, Alessandra
机构
[1] STI/HIV Unit, San Gallicano Dermatological Institute IRCCS, Via Elio Chianesi 53, Rome
[2] Pathology Department, Regina Elena National Cancer Institute IRCCS, Via Elio Chianesi 53, Rome
[3] Infectious, Parasitic and Immunomediated Diseases Department, Istituto Superiore di Sanità, Viale Regina Elena 299, Rome
[4] Microbiology and Clinical Pathology Department, San Gallicano Dermatological Institute IRCCS, Via Elio Chianesi 53, Rome
[5] Scientific Direction, San Gallicano Dermatological Institute IRCCS, Via Elio Chianesi 53, Rome
关键词
D O I
10.1038/s41598-022-14265-z
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
HIV-infected men who have sex with men (MSM) display the highest prevalence of anal infection by high-risk Human Papillomaviruses (hrHPVs) and incidence of anal carcinoma. Anal specimens were genotyped by the Linear Array. Incidence and clearance of anal infection by hrHPVs, hrHPVs other than HPV16, low-risk HPVs, and four individual types (6,11,16,18) were estimated using a two-state Markov model. Determinants for incidence and clearance were assessed by logistic regression. Overall, 204 individuals were included (median age 42 years, IQR = 34–49). For hrHPVs, incidence and clearance rates were 36.1 × 1000 person-months (p-m) (95% CI 23.3–56.5) and 15.6 × 1000 p-m (95% CI 10.7–23.3), respectively. HPV16 showed a higher incidence than HPV18 (10.2 vs. 7.2 × 1000 p-m). Its clearance was more than twofold lower than that of HPV18 (30.1 vs. 78.2 × 1000 p-m). MSM receiving cART displayed a 68% to 88% decrease in risk of acquiring hrHPVs, hrHPVs other than HPV16, HPV16, and HPV18 (adjusted Hazard Ratio [aHR] 0.13, 95% CI 0.02–0.67; aHR 0.22, 95% CI 0.06–0.78; aHR 0.32, 95% CI 0.12–0.90; aHR 0.12, 95% CI 0.04–0.31, respectively) than patients not treated. A nadir CD4 + count < 200 cells/mm3 significantly reduced the clearance of hrHPVs other than HPV16 (aHR 0.39, 95% CI 0.17–0.90). cART use reduces the risk of acquiring anal infection by hrHPVs. © 2022, The Author(s).
引用
收藏
页数:1
相关论文
共 1 条
  • [1] Donà MG, 2022, SCI REP-UK, V12, DOI 10.1038/s41598-021-03913-5